Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Anand Parikh
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 29
- Beta
- -0.28
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 18.91
Financials
Revenue
$0.00Net Income
$-16.01MEBITDA
$-15.98MFree Cash Flow
$-15.67MEPS (diluted)
$-2.84Shares Outstanding (diluted)
5.64M+284.9%Operating Expenses
$18.39MCash & Debt
$186.44MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-21.09M | $-16.72 |
| 2024 | $0.00 | $-30.16M | $-24.01 |
| 2023 | $0.00 | $-34.10M | $-24.40 |
| 2022 | $0.00 | $-48.59M | $-31.65 |
| 2021 | $0.00 | $-36.79M | $-26.56 |
| 2020 | $0.00 | $-20.10M | $-13.21 |
| 2019 | $0.00 | $-16.74M | $-14.01 |
| 2018 | $0.00 | $-13.04M | $-11.49 |
Valuation
FTHhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (3)
- Newsbusinesswire.com·21d ago·Positive
Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH), a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways, today announced that Karen Vousden, Ph.D., has been appointed to its Board of Directors, effective September 11, 2026.“Karen helped shape the scientific thesis this company was built on, and she has been a…
View source ↗ - Newszacks.com·37d ago·Positive
What Makes Faeth Therapeutics, Inc. (FTH) a Strong Momentum Stock: Buy Now? Does Faeth Therapeutics, Inc. (FTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗ - Newszacks.com·45d ago·Neutral
Wall Street Analysts Predict a 72.22% Upside in Faeth Therapeutics, Inc. (FTH): Here's What You Should Know The mean of analysts' price targets for Faeth Therapeutics, Inc. (FTH) points to a 72.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
View source ↗
Earnings
Fri, Nov 13(in 5 weeks)
Consensus estimate $-0.78 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$-2.84 vs $-2.64miss
- Fri, May 15$-131.45 vs $-0.62miss
- Mon, Mar 30$-3.74 vs $-4.81beat
- Fri, Nov 14$-3.62 vs $-4.11beat
- Tue, Aug 5$-3.91 vs $-6.20beat
- Tue, May 6$-5.40 vs $-4.20miss
Estimates and results for FTH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by FTH officers and directors.
- Bought
- $2.4m
- Sold
- $1.7m
47 trades
27 trades
- Stephenson Brian Cbought
- Stephenson Brian Cbought
- Stephenson Brian Cbought
- Stephenson Brian Cbought
- Stephenson Brian Cbought
- Stephenson Brian Cbought
- Stephenson Brian Cbought
- Stephenson Brian Cbought
26 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in FTH.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.